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PCDH10 has been implicated as a tumor suppressor, since epigenetic alterations of this gene have been noted in multiple
tumor types. However, to date, studies regarding its role in acute and chronic leukemias are lacking. Here, we have investi-
gated the presence of promoter hypermethylation of two CpG islands of the PCDH10 gene by methylation-specific PCR in
215 cases of various subsets of myeloid- and lymphoid-lineage leukemias. We found that PCDH10 promoter hypermethyl-
ation was frequent in both B-cell (81.9%) and T-cell (80%) acute lymphoblastic leukemia (ALL), while it was present in low
frequency in most subtypes of myeloid leukemias (25.9%) and rare in chronic myeloid leukemia (2.2%). PCDH10 expression
was downregulated via promoter hypermethylation in primary ALL samples (N ! 4) and leukemia cell lines (N ! 11). The
transcriptional repression caused by PCDH10 methylation could be restored by pharmacologic inhibition of DNA methyl-
transferases. ALL cell lines harboring methylation-mediated inactivation of PCDH10 were less sensitive to commonly used
leukemia-specific drugs suggesting that PCDH10 methylation might serve as a biomarker of chemotherapy response. Our
results demonstrate that PCDH10 is a target of epigenetic silencing in ALL, a phenomenon that may impact lymphoid-line-
age leukemogenesis, serve as an indicator of drug resistance and may also have potential implications for targeted epige-
netic therapy. VC 2011 Wiley Periodicals, Inc.
INTRODUCTION
The protocadherin subfamily of the cadherin
superfamily of genes that encode cadherin-related
neuronal receptors play a role in the establish-
ment and function of specific cell–cell connec-
tions (Yagi, 2008). A number of protocadherin
genes have been implicated as tumor suppressor
genes (Waha et al., 2005; Imoto et al., 2006; Yu
et al., 2008, 2009; Narayan et al., 2009; Cheung
et al., 2010). Recently, it has been shown that
PCDH10 is epigenetically inactivated and func-
tions as a tumor suppressor in multiple human
cancer types, including nasopharyngeal, esopha-
geal, gastric, breast, hepatocellular, and cervical
carcinomas as well as in mature B-cell lympho-
mas (Ying et al., 2006, 2007; Narayan et al., 2009;
Yu et al., 2009; Cheung et al.,2010). PCDH10
methylation occurs early in precancerous stages
of cervical and esophageal cancers suggesting an
important role in tumorigenesis in these tumor
types (Narayan et al., 2009; Yu et al., 2009).
PCDH10 methylation in adjacent normal tissue
was associated with poor survival in gastric cancer
patients and restoration of expression in cell line
exhibits inhibition of tumor growth both in vitro
and in vivo (Yu et al., 2009). Promoter CpG
island hypermethylation-associated gene silencing
has been reported as a frequent event in hemato-
logic malignancies (Garcia-Manero et al., 2009).
Currently, DNA methyltransferase (DNMT)
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inhibitors have been approved for the treatment
of myelodysplastic syndrome (MDS) based on
phase II and phase III studies and these agents
have also shown a good response in acute mye-
loid leukemia (AML) (Oki et al., 2007). Epige-
netic modifications, not only directly or indirectly
affect the gene expression patterns, but specific
genetic changes may also have an impact on epi-
genetic modifications, as in the case of MLL
translocation-associated childhood acute lympho-
blastic leukemia (ALL) (Krivtsov and Armstrong,
2007). As epigenetic mechanisms play critical
roles in disease pathogenesis and serve as useful
targets for epigenetic therapy, there has been
intense focus in understanding the role of epige-
netic modifications in leukemia.
Since epigenetic modifications have been
implicated in leukemogenesis and in the therapy
of leukemia, we have examined promoter hyper-
methylation of PCDH10 in acute myeloid and
lymphoblastic leukemias, MDS, and chronic mye-
loid leukemia (CML). We found differences in
methylation patterns of PCDH10 in a well-charac-
terized cohort comprising various leukemia sub-
types. High frequency of CpG island methylation
was observed in the majority of primary B-cell
and T-cell ALL samples, with a lower frequency
in other leukemia subtypes. Promoter hypermeth-
ylation resulted in downregulated expression of
PCDH10 in ALL cases and cell lines, and ALL
cell lines carrying PCDH10 promoter methylation
exhibited resistance to standard leukemia-specific
drug treatment regimens.
MATERIALS AND METHODS
Patient Samples and Cell Lines
A total of 248 samples were analyzed, which
represented 28 normal bone marrow (N ! 27) or
blood (N ! 1) samples, 77 B-cell ALL, 10 T-cell
ALL, 3 ambiguous lineage leukemia, 59 de novo
AML, 21 MDS, 5 secondary MDS/AML, and 45
CML samples. All specimens used in this study
had been submitted for pathologic and cytoge-
netic evaluation at our institute over a 12-year pe-
riod (July 1997–June 2009). Left over tissue
samples after completion of cytogenetic testing
were stored frozen at –80"C and utilized in the
present study. All specimens were evaluated by
morphology, flow cytometry, and cytogenetic
analyses (Supporting Information Table 1) and
the cases were classified according to the current
WHO criteria (Swerdlow et al., 2008). Data on
clinical outcome and laboratory tests, including
karyotype and FISH findings, treatment informa-
tion were obtained from our institutional
laboratory information systems (Supporting Infor-
mation Table 1). The T-ALL cell lines Jurkat,
CUTLL1, HPB-ALL, MOLT-15, MOLT-16,
P12-ICHIKAWA, KARPAS45, T-ALL1, and
MOLT-4 (kindly provided by Riccardo Dalla-
Favera, Columbia University, New York) and the
B-ALL cell lines RS411 and REH (obtained from
ATCC) were also utilized. All cell lines were
grown in RPMI-1640 containing 10% fetal bovine
serum. The study protocol was approved by our
institutional review board. Frozen specimens and
cell lines were utilized for isolation of high-mo-
lecular-weight DNA and RNA by standard meth-
ods. RNA quality and quantity were assessed by
a bioanalyzer (Agilent Technologies, Foster City,
CA).
Methylation-Specific PCR (MSP)
Two microgram of genomic DNA was con-
verted using EpiTect 96 bisulfite kit (Qiagen, Va-
lencia, CA). Placental DNA treated in vitro with
SssI methyltransferase (New England BioLabs,
Beverly, MA) and normal lymphocyte DNA con-
verted with sodium bisulfite was used as methyl-
ated and unmethylated controls, respectively.
Four sets of primers for amplification of methyl-
ated (M) DNA and two sets of primers for unme-
thylated (U) DNA spanning two CpG Islands
(CGIs) of cDNA clone NM_032961 were
designed (Fig. 1A). The four sets of primers
spanning CGI-2 were described previously (Nar-
ayan et al., 2009). An additional set of methylated
and unmethylated MSP primers spanning CGI-1
was also utilized in the present study (Supporting
Information Table 2).
PCR was performed using standard conditions
for 30 cycles with annealing temperatures varying
between 56 and 62"C. PCR products were run on
2% agarose gels and visualized after ethidium
bromide staining. All MSP experiments were per-
formed in triplicate and promoter hypermethyl-
ation was considered positive when present in at




Quantitative methylation analysis was per-
formed using the Sequenom MALDI-TOF mass
spectrometry platform as per manufacturer speci-
fications (Sequenom). Briefly, 20 ng of bisulfite-
treated genomic DNA was PCR amplified using
T7-promoter tagged primers of three overlapping
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regions spanning the CGI-2. The PCR primers
designed using EpiDesigner software (Sequenom,
Inc. San Diego, CA) for bisulfite converted DNA
were shown in the Supporting Information Table
2.
Five microliters PCR reactions were carried
out in 384-well micro titer plates, treated with 2
ll of Shrimp Alkaline Phosphatase at 0.5 units
concentration followed by brief heat inactivation
and verification of the amplification by agarose
gel. Subsequently, 2 ll of the PCR product was
incubated for 3 hr at 37"C with 5 ll of Mas-
sCLEAVETM mix for concurrent in vitro tran-
scription and base-specific cleavage. Diluted and
resin-cleaned samples were spotted onto the
spectroCHIPV
R
Arrays using the Samsung Mas-
sARRAYTM Nanodispenser and analyzed with
the Sequenom MassARRAY Compact System fol-
lowing 4-point calibration with oligonucleotides
of different masses provided in the Sequenom
kit. In silico fragmentation analysis of RNase A-
digested target sequence for T-cleavage reaction,
on the plus strand, was calculated for each pre-
dicted fragment and used to determine whether
or not the corresponding MALDI-TOF peak
occurs within the useable mass window (default
is 1500–7000 Da). Additionally, fragments that
share the same predicted mass were identified
and flagged, corresponding to ‘‘duplicate or over-
lapping peaks’’ in the EpiTYPER software.
Those fragments that met the defined criteria by
the Sequenom software were flagged appropri-
ately and are treated as CG-containing fragments.
The quantitative fragment mass data generated
by the MALDI-TOF MS and EpiTYPER soft-
ware were further subjected to quality control
analysis. We performed duplicate reactions for
each primer set on all samples analyzed and
found only small variation in methylation levels
of PCDH10 between repeat measurements, thus
Figure 1. Methylation analysis of PCDH10 in leukemia and myelo-
dysplastic syndromes. (A) Genomic region of PCDH10 at 4q28.3 is
shown on top. Below, the coding (thick vertical rectangle), non-cod-
ing (thin vertical rectangle) regions, and the intronic regions (thin hor-
izontal line) for two splice variants are shown. PCDH10-V1 is variant
1and PCDH10-V2 is variant 2. Upward bent arrow indicates tran-
scriptional start site. RT-PCR V1-3 and RT-PCR V2 primer positions
are indicated by head to head arrows. Gray-filled rectangles indicate
CpG islands (CGI-1 and CGI-2). Downward bent arrows indicate
position of methylation primers (MSP4, MSP1, MSP3, and MSP2) and
EpiTyper sequenced region in CGI-2. (B) Patterns of MSP positivity of
various regions in the CpG islands of PCDH10 promoter in normal,
MDS, and various types of leukemia. MSP, methylation specific primer;
MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CML,
chronic myeloid leukemia; ALL, acute lymphoblastic leukemia.
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excluding any possibility of experimental error.
The final data analysis was performed on average
methylation measurements of each informative
CpG derived from duplicate experiments. The
software estimates the relative methylation status
by the sum of the signal-to-noise ratios of the
methylated and unmethylated components. In
each experiment, we included methylated DNA
controls representing 100, 50, 25, and 0 ratios by
combining fully methylated DNA with unmethy-
lated DNA. The methylation fractions obtained
were compatible with the methylated and unme-
thylated DNA ratios. The Sequenom methylation
analysis software and R-Script were used for anal-
ysis of the quantitative measurements where mul-
tiple levels of quality control (QC) were applied.
A Sequenom recommended uncertainty threshold
of 0.01 was applied to the data. CpG units that
yielded data in greater than 75% of the samples
passed initial QC. These data were further fil-
tered to exclude cases that yielded less than 80%
for all informative CpG units within an amplicon/
sample pair. Additionally, CpG units that had
data available for less than 50% of all samples
were excluded. Of the 78 CpGs analyzed, 58
CpGs fulfilled these criteria. The methylation
data generated after QC were used in a one-
dimensional hierarchical clustering analysis. Aver-
age methylation per sample per CpG of all
informative CpGs was calculated after QC analy-
sis. Using this value for each case, mean methyla-
tion index was calculated for the intended
groups.
Drug Treatment
Cells in culture were treated with 5 lM 5-aza-
2’deoxycytidine (5-aza-CdR) for 5 days by replac-
ing the medium everyday, trichostatin (TSA) at a
final concentration of 200 nM for 24 hr and a
combination of both as previously described (Nar-
ayan et al., 2009). Cells collected from these
experiments were used for isolating total RNA.
We determined ICD50 values using 11 ALL cell
lines for the following leukemic drugs: doxorubi-
cin (5 ng/ml), dexamethasone (100 nM), bortezo-
mib (2 ng/ml), methotrexate (50 nM), and L-
asparaginase (2 U/ml). The ALL cell lines were
treated with these drugs for 48 hr to assess cell
viability and apoptosis.
RT-PCR Analysis
Total RNA isolated from normal samples,
leukemia samples, and cell lines were reverse
transcribed as described (Narayan et al., 2009).
Semi-quantitative expression of PCDH10 was per-
formed in triplicate RT-PCR experiments using
the primers shown in Supporting Information Ta-
ble 2 and standard thermal cycle conditions of
initial denaturation at 5 min at 95"C; and 28 to
40 cycles at 30 sec 95"C, 30 sec 56"C, and 30 sec
72"C; and 7 min at 72"C of final extension. Pri-
mers for the b-actin gene were used to assess the
relative intensity of gene expression.
Cell Viability and Apoptosis Assays
Cell viability and cytotoxicity due to each drug
was assessed by standard MTT (3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(Invitrogen, Carlsbad, CA) colorimetric assay.
Briefly, 5000 cells were seeded in 96-well cell
culture plates, grown overnight at 37"C in 5%
CO2 incubator, and treated with indicated con-
centrations of drugs for 48 hr. After incubation of
cells in 5 mg/ml of MTT in phosphate buffer sa-
line for 3.5 hr, the dye was dissolved in 150 ll of
MTT solvent and the optical density of solubi-
lized formazan was assessed using a microplate
reader (BioTek Quant). All treatments were per-
formed in four replicate wells and repeated three






optosis Kit (Invitrogen), which detects the exter-
nalization of phosphatidylserine in apoptotic cells
using recombinant annexin V conjugated to vio-
let-fluorescent Pacific Blue dye and dead cell
using SYTOX AADvanced stain. After staining,
apoptotic cells show violet fluorescence, dead
cells red, and live cells no fluorescence. Briefly,
one million cells were seeded in 6-well tissue cul-
ture plates, grown overnight at 37"C at 5% CO2
incubator, and the indicated concentration of
drugs was added. Cells collected after 48 hr of
incubation were analyzed by a LSR II flow cy-
tometer (BD Biosciences, San Jose, CA) using
405 and 488 nm excitation and 455 and 647 nm
emission. A total of 20,000 events were analyzed
using Flowjo software (Tree Star, OR) in dupli-
cate experiments.
Statistical Analysis
ANOVA and t-test statistics were calculated
using the GraphPad Prism software (LaJolla, CA).
RESULTS
MSP Analysis of PCDH10 in Normal Bone
Marrow, ALL, AML, MDS, and CML
The PCDH10 gene promoter region contains
two classical CpG islands; CGI-1 covering –2133
to –854 bp from the transcription start site (TSS)
and CGI-2 mapped to #367 to #1972 bp from
the TSS of the transcript (Accession No.
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NM_032961.1) in GRCh37 assembly (Fig. 1A).
For qualitative assessment of methylation status
of PCDH10, we performed MSP using three sets
of primers spanning the CGI-2 and one primer
set covering the CGI-1 (Fig. 1A). Promoter hy-
permethylation was examined in 243 DNA sam-
ples derived from normal bone marrow, ALL,
AML, MDS, and CML (Table 1). We identified
hypermethylation in 1 (2.2%) of 45 CML, 2
(9.5%) of 21 MDS, 18 (30.5%) of 59 de novo
AML, 2 (40%) of 5 secondary AML, 3 (100%) of
3 ambiguous lineage leukemias, 59 (81.9%) of 72
B-ALL, and 8 (80%) of 10 T-ALL cases (Table
1). Similar analysis on DNA isolated from 28 nor-
mal samples revealed hypermethylation of CGI-2
in one (3.6%) case. Therefore, these data provide
evidence that a large majority of ALL and ambig-
uous lineage leukemias harbor PCDH10 gene
methylation suggesting that inactivation of this
gene may play a role in the development of these
leukemias. The lower frequencies of promoter
methylation seen in myeloid-lineage disorders
suggest that modifications of DNA methylation
in PCDH10 might not play a role in transforma-
tion or progression (Table 1). To examine if
methylation is uniformly present across the two
CGIs or is restricted to specific regions within a
CGI, we compared the patterns of MSP of the
four regions studied in each specific subtype of
leukemia and MDS (Fig. 1B). This analysis
revealed that methylation was relatively frequent
in CGI-2 that spans exon 1 as compared with
CGI-1 that maps 5’ upstream to the promoter.
Secondly, this analysis also revealed that the pro-
moter methylation was restricted to a smaller
region on CGI-2 in cases of MDS, CML and
secondary AML compared with ALL (Fig. 1B).
Validation of Promoter Methylation Using
Quantitative High-Throughput MALDI-TOF MS
To validate the MSP data and for quantitative
assessment of methylation, we analyzed 96 sam-
ples (Normal, 12; MDS or AML, 18; CML, 11;
B-ALL, 48; T-ALL, 4; and ambiguous lineage
leukemia, 3), that were also analyzed by MSP,
utilizing high-throughput MALDI-TOF MS
methylation analysis (Sequenom). Since the
quantitative values of CpG methylation assess
the methylation of the total sample and thus can
be diluted by normal hematopoietic cells present,
we chose cases that had >50% tumor cells either
by blast count or by FISH positivity for this anal-
ysis. As described above, CGI-2 was more fre-
quently methylated; therefore, we chose this
CpG Island for quantitative methylation covering
78 CpG sites in three amplicons. Of these, 47
CpG sites, which include single CpG sites and
multiple CpGs that fall in one fragment, were
considered informative after MALDI-TOF MS
read out and quality control analysis (Fig. 2A).
Methylation fraction per CpG calculated as
described in Methods (mean # SD) was 0.115 #
0.03 for normal bone marrow specimens, 0.171 #
0.07 for MDS and AML cases, 0.111 # 0.017 for
CML patients, 0.377 # 0.201 for pre B-ALL, and
0.321 # 0.259 for T-ALL and ambiguous lineage
AL (Fig. 2B). The differences in methylation val-
ues between normal samples and CML were not
statistically significant (P ! 0.70), while MDS,
AML, and T-ALL combined with ambiguous lin-
eage AL samples showed marginally significant
differences compared with normal samples (P !
0.01 for both). However, the levels of methyla-
tion were significantly higher in pre B-ALL com-
pared with normal (P ! 0.0001) (Figs. 2A and
2B). Supervised one-way hierarchical cluster anal-
ysis of normal samples showed only one speci-
men that was an outlier (Supporting Information
Figure 1). This was the same specimen that also
exhibited MSP positivity (Table 1). This sample
showed a mean methylation fraction of 0.198
compared with 0.108 of the normal bone marrow
specimens. Supervised analysis of normal and
CML cases showed no distinct differences, a
finding that confirms the MSP data that the pro-
moter of PCDH10 is not methylated in CML
patients. A similar analysis between normal and
MDS/AML samples showed a cluster containing
four specimens with a higher level of methylation
(Fig. 3, top panel). The comparison of normal
with T-ALL samples and ambiguous lineage AL
TABLE 1. Frequency of Promoter Hypermethylation of
PCDH10 in MDS and Leukemia
Type of specimen No. studied Methylated (%)
Normal 28 1 (3.6)
MDS 21 2 (9.5)
Secondary AML 5 2 (40.0)
de novo AML 59 18 (30.5)
CML 45 1 (2.2)
Ambiguous AL 3 3 (100.0)
pre B-ALL 72 59 (81.9)
T-ALL 10 8 (80.0)
MDS, myelodysplastic syndromes; AML, acute myeloid leukemia;
CML, chronic myeloid leukemia; B-ALL, pre B-cell acute lymphoblastic
leukemia; T-ALL, T-cell acute lymphoblastic leukemia; Ambiguous AL,
ambiguous lineage acute leukemia.
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combined resulted in five cases (three T-ALL
and two ambiguous AL) in a specific cluster (Fig.
2A, bottom panel). Analysis of B-ALL resulted in
two distinct clusters (clusters 2 and 3 in Fig. 2A,
middle panel) consisting of 41 (85.4%) of 48 cases
compared with normal. All the samples that
showed high methylation and were clustered by
supervised analysis also scored positive by MSP
analysis. Therefore, the MALDI-TOF MS and
MSP data showed a very close correlation of
methylation between these methods (Supporting
Information Tables 1 and 3). The MDS and leu-
kemia cases that clustered with normal cases
showed a methylation index closer to normal,
while the cases that clustered separately from
normal showed a higher methylation index (Sup-
porting Information Table 3).
PCDH10 Methylation in Relation to Clinical
Parameters and Cytogenetic Subsets of ALL
Since we observed a high frequency of pro-
moter methylation of PCDH10 promoter region in
pre B-and T-ALL, we examined whether methyl-
ation of PCDH10 correlates with various clinical
and cytogenetic features (Supporting Information
Table 1). We did not observe any correlation
with clinical (time to relapse, overall survival,
dead vs. alive) (Supporting Information Figure 3)
or cytogenetic features (abnormal vs. normal
karyotype, complex vs. simple karyotype, specific
translocations, number of changes, ploidy, or
Figure 2. Quantitative analysis of methylation of PCDH10 pro-
moter region in normal bone marrow and in various subtypes of leu-
kemia using Sequenom EpiTYPER. (A) Heat maps showing the one-
dimensional cluster analysis of methylation data generated by Seque-
nom’s MassArray and EpiTyper. Top panel, normal versus MDS/AML,
middle panel, normal versus B-ALL (middle) and bottom panel, nor-
mal versus T-ALL and ambiguous lineage leukemia. CpG Units are
arranged along the x-axis and samples are on the y-axis. Clusters of
methylated cases are indicated by right brackets. Missing data values
are annotated in gray. The red and yellow scale at the bottom repre-
sents the percentage methylation with dark red as lowest methylation
and dark yellow as highest ($100%) methylation. (B) Methylation frac-
tion per sample was calculated (see Methods) and plotted on box-
plot. Significant differences between normal and MDS/AML, T-ALL/
ambiguous lineage acute leukemia (AL), and pre B-ALL were
observed. S, significant; NS, not significant. Box plot shows median,
25th and 75th percentile, minimum, and maximum values.
Figure 3. RT-PCR analysis of PCDH10 expression in ALL. (A) Pri-
mary tumor samples. (B) ALL cell lines. ACTB, ß actin; PCDH10-V1,
variant 1; PCDH10-V2, variant 2. Bracketed M and UM indicates
methylation and unmethylated promoter of PCDH10, respectively.
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presence of any FISH detectable abnormality) by
univariate analysis.
PCDH10 Promoter Hypermethylation Correlates
with Downregulated Transcription in ALL
Specimens and Cell Lines
Promoter hypermethylation of tumor suppres-
sor genes generally results in transcriptional
downregulation of the affected gene. Since a high
frequency of promoter methylation was observed
in both B-ALL and T-ALL cases, we wanted to
examine if levels of PCDH10 transcription were
affected by promoter hypermethylation in these
leukemias. To achieve this, we performed reverse
transcription PCR analysis of the region between
exons 1 and 3 of the PCDH10 transcript variant 1
on a panel of four normal bone marrows, nine
ALL specimens (eight B-ALL and one T-ALL)
using 40 cycles of amplification and 29 cycles for
the b-actin control. All four normal bone marrow
specimens expressed high levels of PCDH10 tran-
scripts relative to control, whereas six (66.7%) of
the nine ALL specimens showed a complete lack
of expression and the remaining three showed
expression levels similar to normal (Fig. 3A). Of
the nine, ALL cases studied by expression, MSP
analysis could be performed only on four cases,
of which three were methylated and one unme-
thylated. The unmethylated case (ALL-9 in Fig.
3A) showed high levels of expression, while all
the three methylated cases showed complete lack
of expression (ALL-3, 4, and 7 in Fig. 3A). Over-
all, these data demonstrate that PCDH10 is down-
regulated in the majority of ALL cases
suggesting that this decreased expression may be
a consequence of promoter methylation.
In addition, we examined the expression of
both variants of PCDH10 in 11 ALL cell lines
(Figs. 1A and 3B). Since variant 2 is a single
intronless exon, RNA isolated from these cell
lines was treated with DNase to avoid DNA
amplification. All the cell lines, except MOLT-
16, showed downregulated expression of either
variant 1 or variant 2, or both. These data further
support the notion that PCDH10 expression is
downregulated in the majority of ALL cell lines.
Pharmacologic Inhibition of DNMTs Reactivates
PCDH10 Expression in ALL Cell Lines
Since downregulated expression of PCDH10
was found in 10 (90.9%) of 11 ALL cell lines, we
wanted to examine its relationship with promoter
methylation utilizing the MSP approach outlined
above and in Figure 1. All the 11 cell lines exhib-
ited promoter methylation of either one or both
the CGIs. Five of the cell lines (CUTLL1,
Jurkat, Karpas-45, MOLT-15, and RS411)
showed no unmethylated allele in CGI-1 and
CGI-2. In addition, three other cell lines (HPB-
ALL, MOLT-4, and P12-Ichikawa) lacked an
unmethylated allele in CGI-2, while they were
present in CGI-1. Two other cell lines (REH and
T-ALL1) showed methylated and unmethylated
alleles in both CGI-1 and CGI-2. The only cell
line that was exclusively positive for methylation
of CGI-1 but not CGI-2 was MOLT-16 (Fig. 4).
This cell line showed no downregulated expres-
sion of either variant 1 or 2 (Figs. 3B and 5).
Taken together these results suggest that methyl-
ation of CGI-2 is critical for transcriptional down-
regulation of PCDH10. These findings also
demonstrate that the cell line data are concordant
with those of the primary ALL specimens regard-
ing the frequency of promoter hypermethylation
and its correlation with downregulated expression
of PCDH10.
Because DNA hypermethylation-mediated
gene silencing is associated with histone modifi-
cations, which can be reactivated by the DNA
demethylating agent 5-aza-CdR and the HDAC
inhibitor trichostatin A (TSA), we tested whether
the promoter hypermethylation-mediated down
regulated PCDH10 expression could be reversed
after treatment with these drugs on ALL cell
lines. We performed varying cycles (28, 30, and
40 cycles for variant 1; 28 and 30 cycles for vari-
ant 2) of semi-quantitative RT-PCR analysis of
DNase-treated total RNA. Of the 11 cell lines
studied, 9 (T-ALL1, MOLT-4, MOLT-15, REH,
P12-Ichikawa, CUTLL1, HPB-ALL, Jurkat, and
RS411) exhibited reactivation of the PCDH10
gene after 5-aza-CdR alone or in combination
with TSA (Fig. 5). Of these nine cell lines, four
Figure 4. Methylation-specific PCR analysis of PCDH10 in ALL cell
lines. Top panel, CGI-1; Bottom panel, CGI-2. MSP, methylation spe-
cific PCR; U, unmethylated primer; M, methylated primer.
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(T-ALL1, MOLT-4, P12-Ichikawa, and Jurkat)
also showed reactivation with TSA alone suggest-
ing a role for chromatin modifications in suppress-
ing PCDH10 transcription. Of the two remaining
cell lines, Karpas45, carrying methylated alleles
of both CGIs, showed no evidence of reactivation
on treatment with any of the drugs. This cell line
showed a relative decrease in expression of both
variants in untreated cells (Figs. 3B and 5). Thus,
the mechanism for the lack of reactivation cannot
be explained by DNA methylation alone and
mutations in upstream regulators or the require-
ment for other transcriptional co-factors cannot
be ruled out. The MOLT-16 cell line that
showed methylation of only CGI-1 did not ex-
hibit downregulated expression and we found no
increase in expression on treatment with any of
the drugs (Fig. 5). None of the treatments had
any affect on the levels of expression of the con-
trol gene. Thus, these data indicate that deme-
thylation of the PCDH10 promoter effectively
reactivates gene expression by reversing the
effect of methylation in most cell lines.
ALL Cell Lines Harboring PCDH10
Methylation and Downregulated Transcription
Exhibit Resistance to Leukemia-Specific
Chemotherapy Drugs
Since the DNA promoter methylation of spe-
cific genes plays a significant role in develop-
ment, progression, and prediction of treatment
responses, we examined the effect of promoter
hypermethylation-associated silencing of PCDH10
on treatment response on a panel of ALL cell
lines after exposing to the standard leukemia-spe-
cific drugs. To test whether PCDH10 promoter-
associated inactivation plays a role in drug resist-
ance in ALL, we analyzed the responses of six
(RS411, Jurkat, CTTLL1, p12-Ichikawa, T-
ALL1, MOLT-16) ALL cell lines chosen based
on their PCDH10 promoter methylation status
and expression to defined doses of doxorubicin,
dexamethasone, bortezomib, methotrexate, and L-
asparaginase. First group consisted of cell lines
T-ALL1 and MOLT-16, which exhibited unme-
thylated promoter of the CGI-2 mapped within
the exon 1 of PCDH10 and expressed high level
Figure 5. Effect of drug treatment using inhibitors of methylation and HDAC on gene reactivation by
RT-PCR analysis in ALL cell lines. Varying cycles of PCR were performed to exclude the possibility of
saturated or undetectable levels of transcript amplification. V1, variant 1; V2, variant 2.
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of transcripts of both variants (Figs. 4 and 5).
The second group consisted of cell lines Jurkat,
P12-Ichikawa, CUTLL1 and RS411 that were
positive for promoter methylation of one or both
CpG islands and a lack or downregulated expres-
sion of both variants (Figs. 4 and 5). The group
containing Jurkat, P12-Ichikawa, CUTLL1, and
RS411 cells exhibiting PCDH10 promoter hyper-
methylation with inactivated transcription was
highly resistant to doxorubicin, methotrexate,
dexamethasone, and bortezomib showing signifi-
cantly high cell viability by MTT assay, while L-
asparaginase showed no significant difference in
cell survival between the two groups (Fig. 6A).
These data suggest that ALL cells with methyla-
tion-mediated inactivation of PCDH10 are resist-
ant to drug-induced response to cell lethality. We
next asked if methylated cell lines also exhibit a
similar resistance in apoptotic response to drug
treatments. Utilizing the Pacific Blue Annexin V
staining method, we showed a significantly
reduced apoptosis in PCDH10 inactivated cell
lines after treatment with doxorubicin, metho-
trexate, and bortezomib compared to unmethy-
lated cell lines (Fig. 6B and Supporting
Information Figure 4). In contrast to the MTT
data, dexamethasone treatment did not show any
difference in apoptotic response between the
methylated and unmethylated cell lines. Similar
to the MTT data, L-asparaginase showed no dif-
ference in apoptosis between epigenetically
silenced and unsilenced cell lines. Together, these
results demonstrate that methylation-mediated
inactivation of PCDH10 negatively influences treat-
ment responses in ALL cell lines.
DISCUSSION
Over the past three decades, the discovery of
acquired karyotypic and genetic changes has
played a crucial role in our understanding of the
biology of hematologic malignancies and has led
to the development of targeted therapies. How-
ever, the role of epigenetic modification and their
interplay with genetic alterations remains poorly
understood in hematologic malignancies. Recent
studies have suggested that specific chromosomal
translocations and gene mutations confer chro-
matin modifications at certain loci, which has led
to the development of therapies influencing
the epigenetic landscape of leukemia (Nowak
et al., 2009). Although cancer cells frequently ex-
hibit hypermethylation of gene promoters and
coding regions, epigenetic changes that underlie
the development of leukemias remain poorly
understood.
The protocadherin gene family members con-
tain six extra cellular cadherin domains, a trans-
membrane domain and a cytoplasmic tail
differing from those of the classical cadherins.
PCDH10, encoding a cadherin-related neuronal
receptor, is thought to play a role in the establish-
ment and function of specific cellular connections
in the brain (Frank and Kemler, 2002). Although
the exact functions of protocadherins are not well
understood, they are believed to play a role in
signal transduction and growth control. Compel-
ling evidence now exists that cadherins play an
important role in tumor progression by function-
ing as suppressors of invasion and metastasis
(Jeanes et al., 2008). The promoter region of the
Figure 6. Analysis of cell viability and apoptosis in ALL cell lines
exposed to leukemic drugs in relation to epigenetic silencing of
PCDH10 gene. Viability assay showing cell survival (A) and cell death
by apoptosis assay (B) in cell lines with unmethylated promoter and
normal expression (T-ALL1 and MOLT-16) and epigenetic silenced cell
lines (Jurkat, P12-Ichikawa, RS411, and CTULL1). Drugs used are L-
asparaginase (ASP), bortezomib (BTZ), doxorubicin (DOX), dexa-
methasone (DEX), and methotrexate (MTX). NS, not significant.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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PCDH10 gene has been shown to be methylated
in a variety of tumors (Waha et al., 2005; Imoto
et al., 2006; Yu et al., 2008, 2009; Narayan et al.,
2009; Cheung et al., 2010). Demethylation or
over expression of PCDH10 significantly inhibits
colony formation and proliferation of solid tumor
cells in vitro (Ying et al., 2006). However, the
role of PCDH10 in leukemia has not been exam-
ined so far.
In the present study, we show that the pro-
moter of PCDH10 is hypermethylated and the
expression of this gene is silenced in the vast ma-
jority of B-cell, T-cell, and ambiguous lineage
AL, while it is absent in CML and infrequent in
other myeloid-lineage leukemia (MDS and
AML). These data therefore suggest that epige-
netic changes in the promoter of PCDH10 differ
between myeloid- and lymphoid-lineage leuke-
mias. The identification of a high frequency of
promoter hypermethylation of PCDH10 in both
B-ALL and T-ALL suggests that inactivation of
this gene most likely plays a role during the neo-
plastic transformation of lymphoid-lineage cells to
leukemic lymphoblasts.
B-ALL represents a highly heterogeneous dis-
ease consisting of different genetic subtypes that
are characterized by specific chromosome translo-
cations (Mrozek et al., 2004). Furthermore, these
genetic subtypes exhibit distinct gene expression
profiles and differ in their response to chemother-
apy and prognosis (Kang et al. 2010). Similarly,
T-ALL is a relatively heterogeneous disease,
although its genetic sub-groups are less well
defined and the patients exhibit overall poor
prognosis (Marks et al., 2009). Thus, there is a
need for better understanding of underlying
genetic and epigenetic alterations in ALL to
design novel therapeutic agents and to predict
prognosis. Epigenetic changes DNA methylation
and chromatin modifications dictate the biological
behavior and response to therapy of cancer cells.
In the present study, we analyzed the methyla-
tion status of PCDH10 to examine its association
with recurrent chromosomal changes such as
ETV6/RUNX1 [t(12;21)], MLL [11q23], BCR/ABL1
[t(9;22)], and ploidy and found no correlation
with specific genetic subtypes (Supporting Infor-
mation Table 1). We also found no differences
between the methylation status of PCDH10 and
overall survival or disease relapse. This observa-
tion reflects the fact that PCDH10 methylation is
common to most ALL cases, and is seen in a
high percentage of patients; thus, this phenom-
enon might represent an early event in leukemo-
genesis for all subtypes of ALL.
Although the role of PCDH10 in cancer has not
been fully elucidated, evidence for the epigenetic
silencing of this gene contributing to tumorigene-
sis has been noted (Ying et al., 2006). Most
recently, PCDH10 was reported to be methylated
in early stages of gastric carcinogenesis and its
methylation was associated with poor prognosis in
gastric cancer patients (Yu et al., 2009). It has
also been shown that silencing of PCDH10
attenuates apoptosis in an imatinib-resistant
CML cell line K562, suggesting that PCDH10
might promote apoptosis. These data suggest that
PCDH10 expression is regulated by hBex1, where
hBex1 over expression in leukemia cells results
in increased expression of PCDH10 (Ding et al.,
2009). Thus, it is conceivable that deregulation of
the hBex1/PCDH10 pathway could play a role in
drug resistance in leukemias. Our present work
implicates a role for PCDH10 methylation in
ALL, since this gene was a target of epigenetic
silencing in the majority of cases and in vitro re-
sistance of ALL cells to leukemic drugs was at-
tributable to epigenetic silencing. Although the
mechanisms underlying cellular resistance to apo-
ptosis in relation to PCDH10 inactivation in ALL
biology remains unclear, our findings provide a
biomarker for chemotherapy resistance that could
facilitate the design of epigenetic strategies to
improve the outcome of treatment refractory
ALL patients. Furthermore, additional mecha-
nisms of inactivation of this gene cannot be
excluded as tumor suppressor genes can be inac-
tivated by multiple mechanisms including
mutations.
Genetic alterations of both B-ALL and T-ALL
have been well characterized illustrating the rela-
tionship between recurrent chromosome changes,
mutations, and gene expression (Mullighan and
Downing, 2009a, b). Although these advances
have led to proper risk stratification and success-
ful treatments, most adult ALL are not cured and
a large proportion of childhood ALL experience
relapse (Fielding et al., 2007; Nguyen et al.,
2008). Identification of additional genetic and
epigenetic pathways is therefore important in
understanding the mechanisms involved in initia-
tion and chemoresistance of ALL. Recent studies
in cancer suggest that epigenetic lesions play a
critical role in leukemogenesis and successful
induction therapy using decitabine in myeloid
leukemias. However, the role of DNMT inhibi-
tors and their efficacy in ALL remains poorly
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understood (Yanez et al., 2009). Dissecting the
mechanisms of drug effect and designing suitable
assays with clinical relevance or prognostic poten-
tial remain major challenges for therapy involving
these agents.
In the present study, we describe the novel
finding of epigenetic silencing of PCDH10 in a
high proportion of ALL and its role in resistance
to standard leukemic drugs, suggesting a role for
PCDH10 in B- and T-cell lymphoblastic leuke-
mogenesis. These findings add to the extant data
regarding the role of epigenetic alterations in
acute leukemias. Further investigations are war-
ranted to explore the role of PCDH10 in ALL
biology and as a potential therapeutic target for
this disease.
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